|
|
|
 |
FDA Approval Activities for this Drug…
Canasa (mesalamine) Suppositories, Axcan Scandipharm NDA 21-252/S2 10/14/03 10/17/03 | Canasa (mesalamine) Suppositories, Axcan Scandipharm NDA 21-252 | Pentasa (Mesalamine) Capsules Roberts NDA 20-049/S006 MESALAMINE Capsule, Extended Release; 250MG PENTASA SHIRE | 019618 MESALAMINE Enema; Rectal 4GM/60ML ROWASA SOLVAY | 021252 MESALAMINE Suppository; Rectal 500MG CANASA AXCAN SCANDIPHARM | 019651 MESALAMINE Tablet, Delayed Release; 400MG ASACOL PROCTER AND GAMBLE Pentasa (meslamine) Controlled Release Capsules, Shire Pharmaceutical, Control Supplement | Mesalamine Rectal Suspension, Clay-Park Labs, Approval | CANASA (mesalamine) Suppository, Axcan Scandipharm, Labeling Revision | Canasa (Mesalamine, USP) Rectal Suppositories, Axcan Scandipharm, New Dosage Regimen | ROWASA (mesalamine) Rectal Suspension Enema, Solvay Pharma, Labeling Revision | Canasa (mesalamine) Suppository, Axcan Scandipharm, Labeling Revision | Pentasa (mesalamine) Controlled-Release Capsules, Shire Dev., Labeling Revision | Lialda (mesalamine) Delayed Release Tablets, Shire Development, Approval | Asacol (mesalamine) Delayed Release Tablets, Procter & Gamble Pharma, Labeling Revision | Mesalamine Rectal Suspension, Perrigo Co., Control Supplement | Pentasa (mesalamine) Controlled-Release Capsules, Shire Dev., Labeling Revision | CANASA (mesalamine) Suppository, Axcan Scandipharma Inc., Package Change | Tradename To Be Determined (mesalamine) Delayed-Release Tablets, Procter & Gamble Pharmaceuticals, Approval | Rowasa (mesalamine) Enema, Alaven Pharmaceutical, LLC, Formulation Revision | Apriso (mesalamine) Extended-Release Capsules, Salix Pharmaceuticals, Inc., Approval | Asacol HD (mesalamine) Delayed-Release Tablets, Procter & Gamble Pharmaceuticals, Inc., Labeling Revision | Lialda (mesalamine) Delayed-Release Tablets, Shire Development Inc., Labeling Revision | Lialda (mesalamine) Delayed-Release Tablet, Shire Development Inc., Labeling Revision | Lialda (mesalamine) Delayed-Release Tablets, Shire Development, Inc., Efficacy Supplement with Clinical Data to Support
  
|